Another clinically trialed therapeutic target, PIK3CA, is the most frequent mutant gene in estrogen receptor (ER)-positive and HER2-negative advanced BC patients [61,62], which was found to link with seven compounds. This evidence concerns the gene PIK3CA and breast cancer.